ADAR1 Capital Management »

Clene shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Clene (CLNN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Clene

Tip: Access up to 7 years of quarterly data

All positions including Clene held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Clene by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $3.4k 12k 0.30

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Clene

AWM Investment Company
Vanguard Group
Alyeska Investment Group
Scoggin
Lunt Capital Management
Citadel Advisors
AE Wealth Management
Susquehanna International
Csenge Advisory Group
Condor Capital Management
SRS Capital Advisors
Millennium Management
CI Private Wealth
Partnership Wealth Management
Key Client Fiduciary Advisors

View all funds holding Clene